Sydney, Australia 23 August 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Dr Gillies O’Bryan-Tear has joined their scientific advisory board.
Dr O’Bryan-Tear joined the pharmaceutical industry in 1986 where he has spent 30 years in clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotech companies, in the US and Europe, and has been involved in multiple product approvals. In 2009 he became Chief Medical Officer of Algeta ASA, a listed Norwegian biotech company developing a radiopharmaceutical for prostate cancer, which was launched worldwide in 2013. Algeta was acquired in 2014 by Bayer AG for US$2.9 billion. Following the acquisition, Dr O’Bryan-Tear left Algeta and has been a retained adviser to a number of US and European biotech companies, and is a member of the Scientific Advisory Boards of Audentes Inc (USA) and Fusion Pharmaceuticals (Canada). Dr O’Bryan-Tear is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and Chair of its Policy and Communications Group, as well as a Fellow of the Royal College of Physicians. He obtained his MD degree from the Universities of Cambridge and London and trained in internal medicine and oncology in the UK.
Dr O’Bryan-Tear commented on his appointment “Clarity has made significant progress in developing its proprietary technology and the use of copper radioisotopes for diagnosis and therapy of cancer and other serious diseases in recent years. The Company has really taken advantage of the rapid growth in the radiopharmaceutical industry and is well positioned to capitalise on its developments to date. I am very excited about joining Clarity’s advisory board at this stage and am looking forward to working with the Company to further progress its clinical trials and assist in product development for a number of diagnostic and therapeutic indications.”
Clarity’s Executive Chairman, Dr Alan Taylor added “We are very excited to welcome Dr O’Bryan-Tear to our advisory board. We believe that his expertise in radiopharmaceutical development and experience working with innovative biotechnology companies with similar products and similar clinical stage of development, like Algeta, will prove invaluable for Clarity. Given Clarity’s growing clinical trial programs, Dr O’Bryan-Tear’s knowledge of clinical development and medical management will significantly help us to achieve our goal of better treating children and adults with cancer.”
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
www.claritypharmaceuticals.com
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
